Skip to content
Search

Latest Stories

OHE report estimates global investment of £3.5bn for research and development of new antibiotic

The current structure of global incentives to develop new antibiotics is insufficient and requires urgent resolution revealed a new report Incentivising new antibiotics’ by the Office of Health Economics (OHE).

OHE analysis demonstrates that on a global level, it is estimated that an effective 10-year incentive would require £3.5bn ($4.2bn) to adequately cover the entire research and development process for a new antibiotic.


The report considers how health systems in the UK and around the world can stimulate the research and development (R&D) of new antibiotics.

In 2020, the National Institute for Health and Care Excellence (NICE) and NHS England initiated an Antimicrobial Resistance pilot with the aim of incentivizing pharmaceutical companies to develop new antibiotics by addressing the issues associated with reimbursement, which historically has deterred companies from pursuing AMR research.

The pilot trialed a subscription-based approach where manufacturers are paid a subscription fee based on the value of the antibiotic, over a pre-specified period, regardless of the volume of antibiotic used. In England, the maximum subscription payment was fixed at £10m per year.

To reach the required level of incentive, individual countries would need to contribute on the basis of the country’s relative wealth and GDP.

The G7 has already committed to a joint agreement on AMR and made a political commitment to action. If all G7 countries contributed to the global incentive, a proportionate UK share would need to be around £23m per year for 10 years. If all G20 countries (and remaining EU countries) contributed to such an incentive, the UK corresponding share would be around £12m/year for 10 years.

Professor Lotte Steuten, Deputy CEO at OHE and co-author of the report said: “The UK is leading the way, but this will not be enough to stimulate antibiotic development on its own. We estimate that £3.5b ($4.2b) is needed globally per antibiotic, which means international political and policy cooperation is needed to create a large enough incentive to drive the development of new antibiotics that will help address the challenge of antimicrobial resistance.”

The modelling in this report highlights the importance of joined up global level efforts to tackle AMR. While the approach taken in England is not the only proposed solution, with other countries developing their own approaches – it was the first of its kind introduced with the aim of fixing the broken antibiotics market. To see significant progress, other countries need to deploy similar approaches, working together to deliver the scale of funding required for a sustainable pipeline of effective antibiotics.

Dr Amit Aggarwal, ABPI Executive Director, Medical Affairs said: “The England AMR pilot has paved the way, showing what is possible when a novel approach for helping overcome AMR is taken forward, and these efforts must not go to waste.

“The learnings from this pilot are important and now is the time for the next stage. The UK continues to have an important role in supporting other countries follow suit by adopting similar schemes, but it cannot do this without collaboration on an international level.”

More For You

The Complete Anti-Inflammatory Guide - a useful resource for pharmacists to support patient health and wellbeing

Chronic inflammation is linked to more than 50 per cent of all deaths worldwide and one in five cancers.

The Complete Anti-Inflammatory Guide - a useful resource for pharmacists to support patient health and wellbeing

When Hemant Patel was struck down by Covid, he was determined to discover what was it that led to the disease having a devastating impact on the lives of people who seemed be healthy – the culmination of his journey is the book, The Complete Anti-Inflammatory Guide.

“I was gasping for breath and counting the number of days I might be alive when I was infected with Covid,” reveals Patel.

Keep ReadingShow less
Cargo plane unloading pharmaceuticals at US airport amid tariff concerns and stockpiling

Imports jumped in particular from Ireland, the top drug exporter to the US

Pic credit: iStock

Pharma imports to US surged in March as drugmakers look to avoid tariffs

Pharmaceutical imports to the US surged in March as drugmakers stocked up ahead of potential US tariffs on their products, which have historically been exempt from such fees.

Total imports of pharmaceutical products exceeded $50 billion in the month - the equivalent of 20 per cent of all pharmaceutical imports in 2024, according to data from a U.S. Commerce Department report on Tuesday.

Keep ReadingShow less
Scottish community pharmacist working in high street pharmacy with supportive environment

The PDA wants investment to reach those who deliver services to patients every day

Pic credit: iStock

Funding boost in Scotland “needs to work for not just pharmacy owners but pharmacists too”, says PDA

An increase in funding for community pharmacies in Scotland needs to lead to a greater focus on supporting pharmacists rather than “simply sustain business models”, according to the Pharmacy Defence Association (PDA).

Earlier this week, Community Pharmacy Scotland (CPS) accepted the Scottish government’s initial financial offer for the 2025/26 fiscal year, securing a guaranteed minimum reimbursement of £120 million for community pharmacies — up from £110 million from 2024/25.

Keep ReadingShow less
GP surgery upgrades for annual appointments

The surgeries will have additional space to “see more patients, boost productivity and improve patient care”

Pic credit: iStock

GP surgery upgrades to create 8.3 million more annual appointments

Over 1,000 GP surgeries will have their premises modernised to meet the needs of a further 8.3 million appointments each year, the government has announced.

Backed by a cash injection of over £102 million, the surgeries will have additional space to “see more patients, boost productivity and improve patient care”.

Keep ReadingShow less
Wales boosts funding for pharmacy-led UTI and sore throat test services

The sore throat test (STTT) and treat service will be widely available

Pic credit: istock

Welsh pharmacies receive funding boost for clinical services

Two key clinical services will be available in 99 per cent of community pharmacies across Wales after a boost in funding.

The sore throat test (STTT) and treat service and the urinary tract infection (UTI) service have both benefitted from contractual negotiations between the Welsh Government and Community Pharmacy Wales (CPW).

Keep ReadingShow less